Dysport ® as an Adjunctive Treatment to Bracing in the Management of Adolescent Idiopathic Scoliosis
Status:
Recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
This study evaluates the combined effect of botulinum toxin A (administered as Dysport®
(Ipsen Pharmaceuticals)) and bracing in children with adolescent idiopathic scoliosis. Two
thirds of patients will be treated with Dysport® and bracing, while the remaining patients
will be treated with placebo and bracing.
Phase:
Phase 4
Details
Lead Sponsor:
Johns Hopkins University
Treatments:
abobotulinumtoxinA Botulinum Toxins Botulinum Toxins, Type A